03 September 2023>: Clinical Research
Association Between Fatty Liver Index, Controlled Attenuation Parameter, and Metabolic Syndrome Stages: A Community-Based Study
Lee-Won Chong 12BDEG , Bagas Suryo Bintoro 34CDEF , Ming-Hsien Tsai 25DF , Yu-Min Lin 12DF , Chyi-Huey Bai 67ABCEG*DOI: 10.12659/MSM.940691
Med Sci Monit 2023; 29:e940691
Table 2 Prevalence rates of metabolic syndrome components categorized, by FLI and CAP.
Metabolic syndrome | Five metabolic syndrome risk factors | |||||||
---|---|---|---|---|---|---|---|---|
Stage A (%) | Stage B (%) | Stage C or D (%) | Elevated WC (%) | Elevated BP (%) | Elevated TG (%) | Elevated FPG (%) | Reduced HDL (%) | |
26.5 | 45.3 | 28.2 | 32.4 | 46.5 | 19.6 | 25.3 | 23.7 | |
Q1 (≤7.6) | 58.1 | 34.9 | 7.0 | 7.0 | 27.9 | 0.0 | 11.6 | 11.6 |
Q2 (7.7–15.1) | 26.2 | 50.0 | 23.8 | 14.3 | 38.1 | 9.5 | 23.8 | 31.0 |
Q3 (15.2–30) | 16.3 | 67.4 | 16.3 | 37.2 | 55.8 | 18.6 | 18.6 | 23.3 |
Q4 (>30) | 4.8 | 28.6 | 66.7 | 71.4 | 64.3 | 52.5 | 47.6 | 29.3 |
Trend | 0.121 | |||||||
Q1 (≤231) | 39.5 | 46.5 | 14.0 | 16.3 | 41.9 | 11.6 | 18.6 | 18.6 |
Q2 (232–277) | 32.6 | 48.8 | 18.6 | 18.6 | 32.6 | 14.3 | 23.3 | 21.4 |
Q3 (278–306) | 23.8 | 50.0 | 26.2 | 35.7 | 57.1 | 19.0 | 19.0 | 23.8 |
Q4 (>306) | 9.5 | 35.7 | 54.8 | 59.5 | 54.8 | 34.1 | 40.5 | 31.0 |
Trend | 0.02 | 0.179 | ||||||
* | ||||||||
S0 (≤215) | 40.0 | 40.0 | 20.0 | 12.0 | 36.0 | 12.0 | 24.0 | 16.0 |
S1 (216–252) | 41.2 | 47.1 | 11.8 | 17.6 | 38.2 | 11.8 | 14.7 | 23.5 |
S2 (253–296) | 25.9 | 50.0 | 24.1 | 27.6 | 48.3 | 21.1 | 22.4 | 24.6 |
S3 (>296) | 11.3 | 41.5 | 47.2 | 56.6 | 54.7 | 26.9 | 35.8 | 26.4 |
Normal | 47.7 | 35.4 | 16.9 | 10.8 | 32.3 | 9.2 | 15.4 | 24.6 |
Mild | 16.1 | 67.9 | 16.1 | 39.3 | 51.8 | 16.4 | 17.9 | 14.5 |
Moderate-severe | 10.2 | 32.7 | 57.1 | 53.1 | 59.2 | 37.5 | 46.9 | 32.7 |
* Based on the definition of clinical classification. FLI – fatty liver index; Q – quarter; S – steatosis; CAP – controlled attenuation parameter; WC – waist circumference; BP – blood pressure; TG – triglyceride; HDL – high-density lipoprotein. |